DATE CREATED: Jun28,2025
Number of Observations: 3
Number of Variables: 40

| **FileName** | **Variable\_label** | **Variable\_Name** | **Category** | **N\_\_Percent** | **Mean\_\_SD** | **Median\_Q1\_Q3** | **Range** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| visu | Blind\_id | Blind\_id |  | 3(100) |  |  |  |
| visu | Blinded\_SiteID | Blinded\_SiteID |  | 3(100) |  |  |  |
| visu | Visit Name | VISNAME | Unscheduled Visit/Call | 3(100) |  |  |  |
| visu | A2. Type: | VISUTYP | Clinic/office visit | 1(33.3) |  |  |  |
| visu | A2. Type: | VISUTYP | Parent/guardian contact | 2(66.7) |  |  |  |
| visu | A2a. Specify other visit type: | VISUTYPO | (Empty string) | 3(100) |  |  |  |
| visu | A3. Visit/call conducted by: | VISUPERS | Site Coordinator | 3(100) |  |  |  |
| visu | A3a. Specify other study member who conducted the visit/call: | VISUPOTH | (Empty string) | 3(100) |  |  |  |
| visu | A4. Reason for visit/call: | VISUREAS | met family at clinic to switch out study medication | 1(33.3) |  |  |  |
| visu | A4. Reason for visit/call: | VISUREAS | This visit was conducted by CO-PI and Site Coordinator. Subject completely month 18 visit remotely however due to COVID did present for safety labs until today | 1(33.3) |  |  |  |
| visu | A4. Reason for visit/call: | VISUREAS | to give new study medication | 1(33.3) |  |  |  |
| visu | A5. Was masking maintained since last visit through the completion of this visit and all associated assessments? | VISUMASK | (Empty string) | 2(66.7) |  |  |  |
| visu | A5. Was masking maintained since last visit through the completion of this visit and all associated assessments? | VISUMASK | Yes | 1(33.3) |  |  |  |
| visu | A6. Were there any changes to adverse events since last visit? | VISUAEYN | (Empty string) | 2(66.7) |  |  |  |
| visu | A6. Were there any changes to adverse events since last visit? | VISUAEYN | No | 1(33.3) |  |  |  |
| visu | A7. Were there any changes to study medication since last visit? | VISUSMYN | (Empty string) | 2(66.7) |  |  |  |
| visu | A7. Were there any changes to study medication since last visit? | VISUSMYN | No | 1(33.3) |  |  |  |
| visu | A7a. Type of change | VISUSMCHG | (Empty string) | 3(100) |  |  |  |
| visu | A8. Were there any changes to concomitant medications since last visit? | VISUCMYN | (Empty string) | 2(66.7) |  |  |  |
| visu | A8. Were there any changes to concomitant medications since last visit? | VISUCMYN | No | 1(33.3) |  |  |  |
| visu | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISUFAMHX | (Empty string) | 2(66.7) |  |  |  |
| visu | B1. Have there been any updates to the participant's family history of premature CVD since last visit? | VISUFAMHX | No | 1(33.3) |  |  |  |
| visu | B1a. Did the total number of the participant's biological relatives with premature CVD change? | VISUHXCHG | (Empty string) | 3(100) |  |  |  |
| visu | B1a1. Total number of biological relatives with premature CVD | VISUHXNUM | (Empty string) | 3(100) |  |  |  |
| visu | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | (Empty string) | 2(66.7) |  |  |  |
| visu | C1. Unexplained and/or persistent muscle pain, tenderness or weakness | SYMMUSCL | Not assessed | 1(33.3) |  |  |  |
| visu | C1a. Is the Unexplained and/or persistent muscle pain, tenderness or weakness associated with recent physical activity or any recent trauma or injury? | SYMUSCINJ | (Empty string) | 3(100) |  |  |  |
| visu | C2. Brown or red urine | SYMURINE | (Empty string) | 2(66.7) |  |  |  |
| visu | C2. Brown or red urine | SYMURINE | Not assessed | 1(33.3) |  |  |  |
| visu | C3. Appearance of fatigue | SYMFATIG | (Empty string) | 2(66.7) |  |  |  |
| visu | C3. Appearance of fatigue | SYMFATIG | Not assessed | 1(33.3) |  |  |  |
| visu | C4. Nausea and/or Vomiting | SYMNAUS | (Empty string) | 2(66.7) |  |  |  |
| visu | C4. Nausea and/or Vomiting | SYMNAUS | Not assessed | 1(33.3) |  |  |  |
| visu | C5. Right upper quadrant pain or tenderness | SYMPAIN | (Empty string) | 2(66.7) |  |  |  |
| visu | C5. Right upper quadrant pain or tenderness | SYMPAIN | Not assessed | 1(33.3) |  |  |  |
| visu | C6. Eosinophilia (> 5%) | SYMEOSIN | (Empty string) | 2(66.7) |  |  |  |
| visu | C6. Eosinophilia (> 5%) | SYMEOSIN | Not assessed | 1(33.3) |  |  |  |
| visu | C7. Elevations in liver enzymes | SYMLIVER | (Empty string) | 2(66.7) |  |  |  |
| visu | C7. Elevations in liver enzymes | SYMLIVER | Not assessed | 1(33.3) |  |  |  |
| visu | C8. Yellow skin or eye discoloration (jaundice) | SYMJAUND | (Empty string) | 2(66.7) |  |  |  |
| visu | C8. Yellow skin or eye discoloration (jaundice) | SYMJAUND | Not assessed | 1(33.3) |  |  |  |
| visu | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | (Empty string) | 2(66.7) |  |  |  |
| visu | C9. Frequent or night-time urination, excessive fatigue and/or excessive thirst | SYMTHRST | Not assessed | 1(33.3) |  |  |  |
| visu | C10. Rash and itching | SYMRASH | (Empty string) | 2(66.7) |  |  |  |
| visu | C10. Rash and itching | SYMRASH | Not assessed | 1(33.3) |  |  |  |
| visu | C11. Diarrhea | SYMDIAR | (Empty string) | 2(66.7) |  |  |  |
| visu | C11. Diarrhea | SYMDIAR | Not assessed | 1(33.3) |  |  |  |
| visu | C12. Constipation | SYMCONST | (Empty string) | 2(66.7) |  |  |  |
| visu | C12. Constipation | SYMCONST | Not assessed | 1(33.3) |  |  |  |
| visu | D1. Was pregnancy/contraceptive counseling discussed with the subject at this visit? | PREGCONS | (Empty string) | 2(66.7) |  |  |  |
| visu | D1. Was pregnancy/contraceptive counseling discussed with the subject at this visit? | PREGCONS | Not assessed | 1(33.3) |  |  |  |
| visu | D2. Did subject confirm abstinence or use of contraceptives measures? | ABSTINYN | (Empty string) | 2(66.7) |  |  |  |
| visu | D2. Did subject confirm abstinence or use of contraceptives measures? | ABSTINYN | Not assessed | 1(33.3) |  |  |  |
| visu | E1. Preventive Cardiology Lifestyle Screener Questionnaire | LIFESTYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E1. Preventive Cardiology Lifestyle Screener Questionnaire | LIFESTYN | No | 1(33.3) |  |  |  |
| visu | E2. Pittsburgh Sleep Quality Index | PSQIYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E2. Pittsburgh Sleep Quality Index | PSQIYN | No | 1(33.3) |  |  |  |
| visu | E3. Data from Fitbit physical activity tracker device? | FBITYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E3. Data from Fitbit physical activity tracker device? | FBITYN | No | 1(33.3) |  |  |  |
| visu | E4. Tanner staging (self report) | TANSYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E4. Tanner staging (self report) | TANSYN | No | 1(33.3) |  |  |  |
| visu | E5. Labs | LABYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E5. Labs | LABYN | No | 1(33.3) |  |  |  |
| visu | E6. Anthropometry, blood pressure measurements | ANTHROPYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E6. Anthropometry, blood pressure measurements | ANTHROPYN | No | 1(33.3) |  |  |  |
| visu | E7. Vascular measures (PWV, CIMT, carotid stiffness) | VASCMYN | (Empty string) | 2(66.7) |  |  |  |
| visu | E7. Vascular measures (PWV, CIMT, carotid stiffness) | VASCMYN | No | 1(33.3) |  |  |  |
| visu | A1. Age at Date of contact | VISUAge |  | 3(100) | 16.8(2.1) | 17.2(15.89,17.91) | 14.58,18.63 |
| visu | C1b. Age at Date of first new muscle symptom | SYMUSAge |  | 0(0) | NaN(NA) | NA(NA,NA) | Inf,-Inf |